| DC66887 |
Zuclopenthixol
Featured
|
Zuclopenthixol ((Z)-Clopenthixol) is a thioxanthene derivative which acts as a mixed dopamine D1/D2 receptor antagonist. |
|
| DC66888 |
S-(2-(2-pyridinyl)ethyl)-L-cysteine
Featured
|
|
|
| DC60653 |
MTX-531
Featured
|
MTX-531 is a potent and selective inhibitor of EGFR and PI3K with IC50 of 15 nM and 6.4 nM, respectively. MTX-531 represents a unique single-molecule approach to balanced combination therapy that minimizes off-target effects while eliminating the need to optimize the pharmacokinetic profiles of multiple agents. |
|
| DC66889 |
Epitalon acetate
Featured
|
Epitalon acetate is a synthetic tetrapeptide with anti-aging properties. Epitalon acetate reduces levels of lipid peroxidation products, delays age-related estrous shutdown, and decreases the frequency of bone marrow cell chromosomal aberrations in female mice. It decreases spontaneous mammary gland and ovarian tumor development and metastasis in aged female mice. Epitalon also stimulates melatonin synthesis and normalizes the circadian rhythm. |
|
| DC60655 |
AK-1690
Featured
|
AK-1690 is the first, potent and selective PROTAC STAT6 degrader with DC50 of 1 nM. AK-1690 displays excellent microsomal and plasma stability, making it a suitable tool compound for in vivo studies. |
|
| DC60656 |
Compound 23 (LRRK2 inhibitor)
Featured
|
Compound 23 (LRRK2 inhibitor) is a potent, selective, and CNS penetrant LRRK2 inhibitor with IC50 of 5 nM. |
.jpg)
|
| DC60657 |
Z6466608628
Featured
|
Z6466608628 is a CRBN molecular gluewith EC50 of 0.34 µM. Z6466608628 selectively recruits PPIL4, along with its binding partner DHX40. |
|
| DC60654 |
CDO1 degrader-1
Featured
|
CDO1 degrader-1 (compound 8) is a molecular glue degrader that targets cysteine dioxygenase (CDO1). |
|
| DC60658 |
ZZ1
Featured
|
ZZ1 is a YPEL5-GID/CTLH-dependent BRD4 degrader with CD50 of 502 nM. ZZ1 induces selective degradation of BET proteins (BRD3 and BRD4). |
|
| DC60659 |
ZZ2
Featured
|
ZZ2 is a YPEL5-GID/CTLH-dependent BRD4 degrader with CD50 of 169 nM. |
|
| DC60660 |
RGT-587
Featured
|
RGT-587 is a CDK inhibitor and selectively inhibits CDK4 but also has excellent brain penetration. |
|
| DC60661 |
RGT-419B
Featured
|
RGT-419B is a CDK inhibitor and not only actively inhibits CDK2, CDK4 and CDK6, but also demonstrates strong anti-proliferation activities. |
|
| A267 |
Sirukumab Biosimilar(Anti-IL-6 / IFNb2 Reference Antibody)
Featured
|
Sirukumab (CNTO-136) is a humanized monoclonal anti-IL6 (Interleukin Related) IgG1κ antibody. Sirukumab binds to IL6, preventing IL6-mediated signal transduction and activation of transcriptional activators, thereby blocking the downstream biological effects of IL6. Sirukumab can be used in the study of active lupus nephritis and rheumatoid arthritis. |
|
| A268 |
Elsilimomab Biosimilar(Anti-IL-6 / IFNb2 Reference Antibody)
Featured
|
Elsilimomab (B-E8) is a IgG1 monoclonal antibody against interleukin-6 (IL-6), with a KD of 22 pM and an IC50 of 1.4 nM. Elsilimomab can be used for the research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA). |
|
| A269 |
Siltuximab Biosimilar (Anti-IL-6 / IFNb2 Reference Antibody)
Featured
|
Siltuximab is an anti-IL-6 (interleukin-6) monoclonal antibody, and shows antitumor activity. Siltuximab can be used in Multicentric Castleman's Disease (MCD) and COVID-19 research. |
|
| A270 |
Olokizumab Biosimilar(Anti-IL-6 / IFNb2 Reference Antibody)
Featured
|
Olokizumab (CDP 6038) is a humanized monoclonal antibody targeting the interleukin-6 (IL-6). Olokizumab can be used in research of rheumatoid arthritis (RA). |
|
| A271 |
Clazakizumab Biosimilar(Anti-IL-6 / IFNb2 Reference Antibody)
Featured
|
Clazakizumab is a monoclonal antibody with high affinity and specificity for the IL-6 (interleukin-6) cytokine. Clazakizumab may be helpful in inhibiting the cytokine response to SARS-CoV-2 in COVID-19. Clazakizumab can be used for the research of psoriatic arthritis (PsA) and renal antibody-mediated rejection. |
|
| A272 |
Chugai SK2 Biosimilar(Anti-IL-6 / IFNb2 Reference Antibody)
Featured
|
|
|
| A275 |
CSTRI patent anti-IL-6 Biosimilar(Anti-IL-6 / IFNb2 Reference Antibody)
Featured
|
|
|
| A276 |
Medarex patent anti-IL-6 Biosimilar(Anti-IL-6 / IFNb2 Reference Antibody)
Featured
|
|
|
| A277 |
MEDI 5117 Biosimilar(Anti-IL-6 / IFNb2 Reference Antibody)
Featured
|
|
|
| A278 |
Merck patent anti-IL-6 Biosimilar(Anti-IL-6 / IFNb2 Reference Antibody)
Featured
|
|
|
| A129 |
Sarilumab Biosimilar(Anti-IL-6Ra / CD126 Reference Antibody)
Featured
|
Sarilumab (Anti-Human IL6Rα, Human Antibody) is a human immunoglobulin G1 monoclonal antibody. Sarilumab, a interleukin-6 (IL-6) receptor antagonist, binds to the IL-6 receptor with high affinity and inhibits cis and trans signaling by IL-6, resulting in reduced inflammation. Sarilumab can be used for the research of Rheumatoid arthritis. |
|
| A279 |
Levilimab Biosimilar(Anti-IL-6Ra / CD126 Reference Antibody)
Featured
|
Levilimab (BCD-089) is a fully humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody. Levilimab is an inflammation-alleviating antibody. Levilimab can be used for the research of rheumatoid. |
|
| A280 |
APX-007 Biosimilar(Anti-IL-6Ra / CD126 Reference Antibody)
Featured
|
|
|
| A281 |
Vobarilizumab Biosimilar(Anti-IL-6Ra / CD126 Reference Antibody)
Featured
|
Vobarilizumab (ALX-0061) is a humanized bispecific anti-IL-6R and anti-human serum albumin (ALB) monoclonal antibody (mAb) (Kd: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis. |
|
| A282 |
Sapelizumab Biosimilar(Anti-IL-6Ra / CD126 Reference Antibody)
Featured
|
|
|
| A283 |
PF-06342674 Biosimilar(Anti-IL-7Ra / CD127 Reference Antibody）
Featured
|
|
|
| A284 |
Lusvertikimab Biosimilar（Anti-IL-7Ra / CD127 Reference Antibody）
Featured
|
Lusvertikimab (OSE-127) is a humanized IL7R monoclonal antibody. Lusvertikimab is not internalized by target cells and prevents IL7R heterodimerization and subsequent downstream signaling. Lusvertikimab has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research. |
|
| A285 |
Bapotulimab Biosimilar(Anti-ILDR2 Reference Antibody)
Featured
|
Bapotulimab (BAY-1905254) is a fully human IgG2 antibody targeting immunoglobulin-like domain containing receptor 2 (ILDR2). Bapotulimab has antitumor and immunosuppressive effects. |
|
